Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.
Regula JT, et al. Among authors: iwata d.
EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov.
EMBO Mol Med. 2016.
PMID: 27742718
Free PMC article.